SEC Form SC14D9C filed by bluebird bio Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
bluebird bio, Inc.
(Name of Subject Company)
bluebird bio, Inc.
(Name of Person(s) Filing Statement)
Common Stock, $0.01 par value per share
(Title of Class of Securities)
09609G 209
(CUSIP Number of Common Stock)
Andrew Obenshain
President and Chief Executive Officer
bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, Massachusetts 02145
(339) 499-9300
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person(s) Filing Statement)
With a copy to:
R. Scott Shean
Andrew Clark
Brian R. Umanoff
Latham & Watkins LLP
650 Town Center Drive, 20th Floor
Boston, Massachusetts 92626
(714) 540-1235
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by bluebird bio, Inc. on February 21, 2025 (including all exhibits attached thereto) is incorporated herein by reference.